Systemic fungal infections: A pharmacist/researcher perspective |
| |
| Institution: | 1. Departamento de Bioquímica e Biologia Molecular, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, 74690-900, Goiás, Brazil;2. Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, 06536, USA;1. Division of Biological Science, Faculty of Science and Technology, Huachiew Chalermprakiet University, Samut-Prakarn 10540, Thailand;2. Department of Microbiology, Faculty of Science, Srinakharinwirot University, Bangkok 10110, Thailand;3. Department of Microbiology, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand;4. Biodiversity Center Kasetsart University (BDCKU), Bangkok 10900, Thailand;5. Academy of Science, The Royal Society of Thailand, Bangkok, 10300, Thailand;1. Department of Forest Mycology and Plant Pathology, Uppsala Biocenter, Swedish University of Agricultural Sciences, Box 7026, SE-750 07 Uppsala, Sweden;2. Department of Plant Biology, Uppsala Biocenter, Swedish University of Agricultural Sciences, Linnean Center for Plant Biology, Box 7080, S-75007, Uppsala, Sweden;1. Jiangsu Key Laboratory for Microbes and Functional Genomics, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China;2. Jiangsu Key Laboratory for Microbes and Functional Genomics, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China |
| |
| Abstract: | Systemic fungal infections are increasing in prevalence, especially in immunocompromised patients and post-surgical patients. The rise in systemic fungal infections has resulted in increased utilization of antifungal agents which, in turn, has contributed to escalating resistance rates as seen by the increasing number of fungal pathogens added to the Centers for Disease Control and Prevention Antimicrobial Resistance Threats Report in 2019. Unfortunately, there are few novel antifungal agents coming to market to combat these ever-increasing resistance rates. In this review, we cover the current climate of antifungal agents and explore agents coming through the pipeline and potentially to market. We also discuss the indicated uses for empiric and targeted antifungal therapies as well as the need to include antifungal agents as a part of antimicrobial stewardship programs that focus heavily on antibacterial agents. |
| |
| Keywords: | Antifungal agent Mechanism of action Systemic antifungal coverage Systemic fungal infections Stewardship |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
